Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: serestherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $6.00 | Buy → Neutral | Chardan Capital Markets |
| 10/24/2024 | Neutral → Underweight | JP Morgan | |
| 6/26/2023 | $12.00 | Outperform | Oppenheimer |
| 4/21/2023 | $7.00 | Neutral | JP Morgan |
| 7/23/2021 | $42.00 → $29.00 | Buy | Canaccord Genuity |
| 7/23/2021 | $30.00 → $16.00 | Buy | Chardan Capital |
| 7/23/2021 | $36.00 → $18.00 | Outperform | Oppenheimer |
| 7/23/2021 | $46.00 → $25.00 | Buy | HC Wainwright & Co. |
| 7/23/2021 | $24.00 → $7.00 | Neutral → Sell | Goldman Sachs |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
3 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
SCHEDULE 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
SCHEDULE 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
S-8 - Seres Therapeutics, Inc. (0001609809) (Filer)
10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
Fastest customizable press release news feed in the world
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Thomas DesRosier and Marella Thorell as co-Ch
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 –June 3 in Chicago. The Company previously reported exploratory biomarker data from the SER-155 Phase 1b study showing evidence of improved intestinal epithelial barrier integrity and modulation of systemic inflammatory responses. The results are consistent with SER-155's intended therapeutic mechanisms to reduce the r
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New resu
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately tw
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study Seres has submitted clarification questions to FDA and expects a response in the coming weeks, which will inform the proposed protocol for the next SER-155 study in allo-HSCT, which the Company anticipates submitting to FDA in Q2 CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced that it has received constructive feedback from a Typ
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00
JP Morgan downgraded Seres Therapeutics from Neutral to Underweight
Oppenheimer resumed coverage of Seres Therapeutics with a rating of Outperform and set a new price target of $12.00
JP Morgan initiated coverage of Seres Therapeutics with a rating of Neutral and set a new price target of $7.00
Canaccord Genuity reiterated coverage of Seres Therapeutics with a rating of Buy and set a new price target of $29.00 from $42.00 previously
Chardan Capital reiterated coverage of Seres Therapeutics with a rating of Buy and set a new price target of $16.00 from $30.00 previously
Oppenheimer reiterated coverage of Seres Therapeutics with a rating of Outperform and set a new price target of $18.00 from $36.00 previously
HC Wainwright & Co. reiterated coverage of Seres Therapeutics with a rating of Buy and set a new price target of $25.00 from $46.00 previously
Goldman Sachs downgraded Seres Therapeutics from Neutral to Sell and set a new price target of $7.00 from $24.00 previously
Goldman resumed coverage of Seres Therapeutics with a rating of Neutral and set a new price target of $24.00
Live finance-specific insights
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours afte
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately tw
SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT Financial position strengthened following completion of VOWST™ sale; based on existing cash, projected 2025 deal economics and current operating plans, Seres expects to fund operations into Q4 2025 Seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIR
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5051385. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated safety profile and confirmed drug bacteria strain engraftment; no treatment-related serious adverse events Company to seek Breakthrough Therapy designation from the FDA, given the high unmet medical need associated with BSIs, and discuss plans to advance development of SER-155 in allo-HSCT Results support Seres' strategy to pursue SER-155 and other live biotherapeutics for prevention of a broader range of
SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations between the Parties, at close Transaction proceeds to fully retire debt and support advancement of wholly-owned cultivated live biotherapeutic pipeline to improve patient outcomes in medically vulnerable populations Based on existing cash, deal economics and operating plans, Seres expects to fund operations into Q4 2025 Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or "the Company"),
This live feed shows all institutional transactions in real time.
SC 13D/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI. “Today’s approval provides patients and healthcare p
Live Leadership Updates
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Thomas DesRosier and Marella Thorell as co-Ch
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both public and private companies. Prior to joining Seres, she served in executive positions with Evelo Biosciences, Centessa Pharmaceuticals, Palladio Biosciences and Realm Therapeutics. "I am excited to welcome Marella and look forward
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t
ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy. "Partner
CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development. Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets inc
CAMBRIDGE, Mass., Aug. 14, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act specifically at the site of disease and nowhere else, today announced that Jason Gardner, Ph.D., has joined Flagship Pioneering as CEO-Partner, and Ampersand as Chief Executive Officer and member of its Board of Directors. Gardner brings more than two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a succ